{"pmid":32426877,"title":"Metastatic melanoma treatment with check point inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit.","text":["Metastatic melanoma treatment with check point inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit.","Melanoma epidemiology has shown a constant increase in the last few decades even if mortality is low and only a small percentage of patients develop metastatic disease. For these patients, immunotherapy with checkpoint inhibitors (ICI) significantly improves disease outcome with a median survival more than 2 years. The same drugs are used as adjuvant treatment in disease-free patients. Coronavirus Disease-19 (COVID-19) is now a pandemic disease with lung manifestations, which can bring severe acute respiratory distress. The most important risk factors related to a higher death risk for COVID-19 pneumonia are elderly age and comorbidities (hypertension, diabetes, previous cancer).","J Eur Acad Dermatol Venereol","Quaglino, Pietro","Fava, Paolo","Brizio, Matteo","Marra, Elena","Rubatto, Marco","Agostini, Andrea","Tonella, Luca","Ribero, Simone","Fierro, Maria Teresa","32426877"],"abstract":["Melanoma epidemiology has shown a constant increase in the last few decades even if mortality is low and only a small percentage of patients develop metastatic disease. For these patients, immunotherapy with checkpoint inhibitors (ICI) significantly improves disease outcome with a median survival more than 2 years. The same drugs are used as adjuvant treatment in disease-free patients. Coronavirus Disease-19 (COVID-19) is now a pandemic disease with lung manifestations, which can bring severe acute respiratory distress. The most important risk factors related to a higher death risk for COVID-19 pneumonia are elderly age and comorbidities (hypertension, diabetes, previous cancer)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Quaglino, Pietro","Fava, Paolo","Brizio, Matteo","Marra, Elena","Rubatto, Marco","Agostini, Andrea","Tonella, Luca","Ribero, Simone","Fierro, Maria Teresa"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426877","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jdv.16586","locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1667252837773475841,"score":9.490897,"similar":[{"pmid":32434789,"title":"Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy.","text":["Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy.","BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed with stage IV melanoma who developed pulmonary and brain metastases and was treated with bilateral craniotomies followed by combined nivolumab and ipilimumab immunotherapy. He developed early-onset severe dyspnea associated with acute coronavirus HKU1 (non-COVID-19) infection, with diffuse pneumonitis evidenced by ground glass opacification on CT scan. He was treated with steroids leading to resolution of pneumonitis on repeat imaging, suggesting an exacerbated immune-mediated toxicity. CONCLUSION: We report the first case of a patient with melanoma with severe and reversible diffuse pneumonitis in association with coronavirus HKU1 following combined nivolumab and ipilimumab immunotherapy. Although we do not have data on the impact of ICI therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatology, a possible interaction should be considered when deciding on dosing in patients with possible SARS-CoV-2 exposure or when evaluating patients with presumed ICI-related pneumonitis during the COVID-19 pandemic.","J Immunother Cancer","Serzan, Michael T","Kumar, Princy N","Atkins, Michael B","32434789"],"abstract":["BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed with stage IV melanoma who developed pulmonary and brain metastases and was treated with bilateral craniotomies followed by combined nivolumab and ipilimumab immunotherapy. He developed early-onset severe dyspnea associated with acute coronavirus HKU1 (non-COVID-19) infection, with diffuse pneumonitis evidenced by ground glass opacification on CT scan. He was treated with steroids leading to resolution of pneumonitis on repeat imaging, suggesting an exacerbated immune-mediated toxicity. CONCLUSION: We report the first case of a patient with melanoma with severe and reversible diffuse pneumonitis in association with coronavirus HKU1 following combined nivolumab and ipilimumab immunotherapy. Although we do not have data on the impact of ICI therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatology, a possible interaction should be considered when deciding on dosing in patients with possible SARS-CoV-2 exposure or when evaluating patients with presumed ICI-related pneumonitis during the COVID-19 pandemic."],"journal":"J Immunother Cancer","authors":["Serzan, Michael T","Kumar, Princy N","Atkins, Michael B"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434789","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/jitc-2020-000898","keywords":["case reports","immunomodulation","immunotherapy","melanoma"],"e_drugs":["Steroids","Nivolumab","Ipilimumab"],"topics":["Treatment"],"weight":1,"_version_":1667521393798938624,"score":191.72688},{"pmid":32290754,"pmcid":"PMC7161588","title":"Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?","text":["Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?","The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents.","Immunotherapy","Kattan, Joseph","Kattan, Clarisse","Assi, Tarek","32290754"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents."],"journal":"Immunotherapy","authors":["Kattan, Joseph","Kattan, Clarisse","Assi, Tarek"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290754","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.2217/imt-2020-0077","keywords":["covid-19","cancer","checkpoints inhibitors","coronavirus","immune therapy","immunosuppression"],"topics":["Treatment"],"weight":1,"_version_":1666138494474387457,"score":160.35358},{"pmid":32434790,"title":"COVID-19 and immune checkpoint inhibitors: initial considerations.","text":["COVID-19 and immune checkpoint inhibitors: initial considerations.","COVID-19 infections are characterized by inflammation of the lungs and other organs that ranges from mild and asymptomatic to fulminant and fatal. Patients who are immunocompromised and those with cardiopulmonary comorbidities appear to be particularly afflicted by this illness. During pandemic conditions, many aspects of cancer care have been impacted. One important clinical question is how to manage patients who need anticancer therapy, including immune checkpoint inhibitors (ICIs) during these conditions. Herein, we consider diagnostic and therapeutic implications of using ICI during this unprecedented period of COVID-19 infections. In particular, we consider the impact of ICI on COVID-19 severity, decisions surrounding continuing or interrupting therapy, diagnostic measures in patients with symptoms or manifestations potentially consistent with either COVID-19 or ICI toxicity, and resumption of therapy in infected patients. While more robust data are needed to guide clinicians on management of patients with cancer who may be affected by COVID-19, we hope this commentary provides useful insights for the clinical community.","J Immunother Cancer","Sullivan, Ryan J","Johnson, Douglas B","Rini, Brian I","Neilan, Tomas G","Lovly, Christine M","Moslehi, Javid J","Reynolds, Kerry L","32434790"],"abstract":["COVID-19 infections are characterized by inflammation of the lungs and other organs that ranges from mild and asymptomatic to fulminant and fatal. Patients who are immunocompromised and those with cardiopulmonary comorbidities appear to be particularly afflicted by this illness. During pandemic conditions, many aspects of cancer care have been impacted. One important clinical question is how to manage patients who need anticancer therapy, including immune checkpoint inhibitors (ICIs) during these conditions. Herein, we consider diagnostic and therapeutic implications of using ICI during this unprecedented period of COVID-19 infections. In particular, we consider the impact of ICI on COVID-19 severity, decisions surrounding continuing or interrupting therapy, diagnostic measures in patients with symptoms or manifestations potentially consistent with either COVID-19 or ICI toxicity, and resumption of therapy in infected patients. While more robust data are needed to guide clinicians on management of patients with cancer who may be affected by COVID-19, we hope this commentary provides useful insights for the clinical community."],"journal":"J Immunother Cancer","authors":["Sullivan, Ryan J","Johnson, Douglas B","Rini, Brian I","Neilan, Tomas G","Lovly, Christine M","Moslehi, Javid J","Reynolds, Kerry L"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434790","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/jitc-2020-000933","keywords":["cytotoxicity, immunological"],"topics":["Treatment"],"weight":1,"_version_":1667521393781112833,"score":150.61737},{"pmid":32423324,"title":"Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.","text":["Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.","Outbreak of the new type coronavirus infection, known as coronavirus infection 2019 (COVID-19), has begun in December 2019, in Wuhan, China. As of today, 3 April 2020, 972,640 people affected and 50,325 people died from Severe Acute Respiratory Syndrome-Coronavirus 2. There is not any standard treatment for coronavirus infection 2019; however, there are promising data for hydroxychloroquine and some anti-retroviral drugs. Programmed death-1 (PD-1)/programmed death ligand-1 (PDL-1) pathway is an important target for the cancer immunotherapy. However, there is a robust pre-clinical and clinical data regarding inhibitor effect of this pathway on the acute or chronic viral infections. Thus, blockade of this pathway may lead to an anti-viral effect and decrease viral load. Here, we report the clinical course of coronavirus infection 2019 infection of a patient in whom older aged, having multiple co-morbidities, and taking nivolumab for metastatic malignant melanoma. In contrast to her older age, comorbidities, and cancer diagnosis, she was in a good condition, and there was also no pneumonia finding. We think that this good clinical course of coronavirus infection 2019 infection may be related to blockade of PD-1/PDL-1 pathway with nivolumab. It is impossible to say that blockade of PD-1/PDL-1pathway is a treatment option for COVID-19; however, we want to share our experience.","J Oncol Pharm Pract","Yekeduz, Emre","Dursun, Bengu","Aydin, Gule C","Yazgan, Sati C","Ozturk, Halis H","Azap, Alpay","Utkan, Gungor","Urun, Yuksel","32423324"],"abstract":["Outbreak of the new type coronavirus infection, known as coronavirus infection 2019 (COVID-19), has begun in December 2019, in Wuhan, China. As of today, 3 April 2020, 972,640 people affected and 50,325 people died from Severe Acute Respiratory Syndrome-Coronavirus 2. There is not any standard treatment for coronavirus infection 2019; however, there are promising data for hydroxychloroquine and some anti-retroviral drugs. Programmed death-1 (PD-1)/programmed death ligand-1 (PDL-1) pathway is an important target for the cancer immunotherapy. However, there is a robust pre-clinical and clinical data regarding inhibitor effect of this pathway on the acute or chronic viral infections. Thus, blockade of this pathway may lead to an anti-viral effect and decrease viral load. Here, we report the clinical course of coronavirus infection 2019 infection of a patient in whom older aged, having multiple co-morbidities, and taking nivolumab for metastatic malignant melanoma. In contrast to her older age, comorbidities, and cancer diagnosis, she was in a good condition, and there was also no pneumonia finding. We think that this good clinical course of coronavirus infection 2019 infection may be related to blockade of PD-1/PDL-1 pathway with nivolumab. It is impossible to say that blockade of PD-1/PDL-1pathway is a treatment option for COVID-19; however, we want to share our experience."],"journal":"J Oncol Pharm Pract","authors":["Yekeduz, Emre","Dursun, Bengu","Aydin, Gule C","Yazgan, Sati C","Ozturk, Halis H","Azap, Alpay","Utkan, Gungor","Urun, Yuksel"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423324","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/1078155220924084","keywords":["covid-19","sars-cov2","immunotherapy"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Nivolumab","Hydroxychloroquine"],"topics":["Case Report"],"weight":1,"_version_":1667352728920129537,"score":145.0339},{"pmid":32460421,"title":"Hypofractionated radiotherapy in patients with non-melanoma skin cancer in the post COVID-19 era: Time to reconsider its role for most patients.","text":["Hypofractionated radiotherapy in patients with non-melanoma skin cancer in the post COVID-19 era: Time to reconsider its role for most patients.","The most frequent cancer worldwide is skin cancer, occurring at epidemic rates in countries exposed to high levels of chronic ultraviolet radiation such as Australia and New Zealand (ANZ). Australia has the highest incidence of non-melanoma skin cancer (NMSC) in the world. NMSC is predominantly a cancer of the middle aged or elderly and accounts for considerable consulting and treatment time in most radiation oncology departments. Many patients also suffer from medical co-morbidity, an important factor in any treatment decision.","J Med Imaging Radiat Oncol","Veness, Michael","32460421"],"abstract":["The most frequent cancer worldwide is skin cancer, occurring at epidemic rates in countries exposed to high levels of chronic ultraviolet radiation such as Australia and New Zealand (ANZ). Australia has the highest incidence of non-melanoma skin cancer (NMSC) in the world. NMSC is predominantly a cancer of the middle aged or elderly and accounts for considerable consulting and treatment time in most radiation oncology departments. Many patients also suffer from medical co-morbidity, an important factor in any treatment decision."],"journal":"J Med Imaging Radiat Oncol","authors":["Veness, Michael"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460421","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/1754-9485.13070","locations":["Australia","New Zealand","Australia"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1667967699055017984,"score":112.36749}]}